OPT Stock Overview
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia.
Opthea Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.38|
|52 Week High||AU$1.48|
|52 Week Low||AU$0.79|
|1 Month Change||20.52%|
|3 Month Change||14.52%|
|1 Year Change||11.29%|
|3 Year Change||-46.92%|
|5 Year Change||66.27%|
|Change since IPO||2,200.00%|
Recent News & Updates
Is Opthea (ASX:OPT) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
|OPT||AU Biotechs||AU Market|
Return vs Industry: OPT exceeded the Australian Biotechs industry which returned -1.3% over the past year.
Return vs Market: OPT exceeded the Australian Market which returned -8% over the past year.
|OPT Average Weekly Movement||9.1%|
|Biotechs Industry Average Movement||11.7%|
|Market Average Movement||10.5%|
|10% most volatile stocks in AU Market||17.6%|
|10% least volatile stocks in AU Market||4.6%|
Stable Share Price: OPT is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: OPT's weekly volatility (9%) has been stable over the past year.
About the Company
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company’s development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases.
Opthea Limited Fundamentals Summary
|OPT fundamental statistics|
Is OPT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|OPT income statement (TTM)|
|Cost of Revenue||US$392.58k|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.16|
|Net Profit Margin||518,374.03%|
How did OPT perform over the long term?See historical performance and comparison